Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2006 1
2007 2
2009 3
2010 13
2011 14
2012 16
2013 11
2014 14
2015 13
2016 17
2017 15
2018 14
2019 12
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

131 results
Results by year
Filters applied: . Clear all
Page 1
Ulipristal acetate versus leuprolide acetate for uterine fibroids.
Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, Nouri K, Selvaggi L, Sodowski K, Bestel E, Terrill P, Osterloh I, Loumaye E; PEARL II Study Group. Donnez J, et al. N Engl J Med. 2012 Feb 2;366(5):421-32. doi: 10.1056/NEJMoa1103180. N Engl J Med. 2012. PMID: 22296076 Free article. Clinical Trial.
Median times to amenorrhea were 7 days for patients receiving 5 mg of ulipristal acetate, 5 days for those receiving 10 mg of ulipristal acetate, and 21 days for those receiving leuprolide acetate. Moderate-to-severe hot flashes were reported for 11% of patients rec …
Median times to amenorrhea were 7 days for patients receiving 5 mg of ulipristal acetate, 5 days for those receiving 10 mg of ulip
Choice of contraceptives.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2018 Oct 8;60(1557):161-168. Med Lett Drugs Ther. 2018. PMID: 30335731 No abstract available.
Long-term medical management of uterine fibroids with ulipristal acetate.
Donnez J, Donnez O, Matule D, Ahrendt HJ, Hudecek R, Zatik J, Kasilovskiene Z, Dumitrascu MC, Fernandez H, Barlow DH, Bouchard P, Fauser BC, Bestel E, Loumaye E. Donnez J, et al. Fertil Steril. 2016 Jan;105(1):165-173.e4. doi: 10.1016/j.fertnstert.2015.09.032. Epub 2015 Oct 23. Fertil Steril. 2016. PMID: 26477496 Free article. Clinical Trial.
OBJECTIVE: To investigate the efficacy and safety of repeated 12-week courses of 5 or 10 mg daily ulipristal acetate for intermittent treatment of symptomatic uterine fibroids. ...Pain and QoL showed marked improvements from screening, even during the off-treatment interva …
OBJECTIVE: To investigate the efficacy and safety of repeated 12-week courses of 5 or 10 mg daily ulipristal acetate for intermittent …
Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Jilla MP, Bestel E, Terrill P, Osterloh I, Loumaye E; PEARL I Study Group. Donnez J, et al. N Engl J Med. 2012 Feb 2;366(5):409-20. doi: 10.1056/NEJMoa1103182. N Engl J Med. 2012. PMID: 22296075 Free article. Clinical Trial.
Serious adverse events occurred in one patient during treatment with 10 mg of ulipristal acetate (uterine hemorrhage) and in one patient during receipt of placebo (fibroid protruding through the cervix). Headache and breast tenderness were the most common adverse
Serious adverse events occurred in one patient during treatment with 10 mg of ulipristal acetate (uterine hemorrhage) and in o …
Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis.
Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E. Glasier AF, et al. Lancet. 2010 Feb 13;375(9714):555-62. doi: 10.1016/S0140-6736(10)60101-8. Epub 2010 Jan 29. Lancet. 2010. PMID: 20116841 Clinical Trial.
In 203 women who received emergency contraception between 72 h and 120 h after sexual intercourse, there were three pregnancies, all of which were in the levonorgestrel group. The most frequent adverse event was headache (ulipristal acetate, 213 events [19.3%] in 11 …
In 203 women who received emergency contraception between 72 h and 120 h after sexual intercourse, there were three pregnancies, all of whic …
Emergency Contraception.
Batur P, Kransdorf LN, Casey PM. Batur P, et al. Mayo Clin Proc. 2016 Jun;91(6):802-7. doi: 10.1016/j.mayocp.2016.02.018. Mayo Clin Proc. 2016. PMID: 27261868 Review.
There are 4 approved EC options in the United States. Although ulipristal acetate requires a provider's prescription, oral levonorgestrel (LNG) is available over the counter for women of all ages. ...Women who weigh more than 75 kg or have a body mass index greater than 25 …
There are 4 approved EC options in the United States. Although ulipristal acetate requires a provider's prescription, oral levonorges …
Endometrial changes during ulipristal acetate use: A systematic review.
De Milliano I, Van Hattum D, Ket JCF, Huirne JAF, Hehenkamp WJK. De Milliano I, et al. Eur J Obstet Gynecol Reprod Biol. 2017 Jul;214:56-64. doi: 10.1016/j.ejogrb.2017.04.042. Epub 2017 Apr 28. Eur J Obstet Gynecol Reprod Biol. 2017. PMID: 28482329 Review.
Several studies have been performed to evaluate this possible increased risk for endometrial malignancies when using ulipristal acetate. The specific spectrum of morphological changes due to ulipristal acetate, named progesterone receptor modulator associated endome …
Several studies have been performed to evaluate this possible increased risk for endometrial malignancies when using ulipristal aceta …
Limbo.
Schorge JO. Schorge JO. Obstet Gynecol. 2018 Jun;131(6):959-960. doi: 10.1097/AOG.0000000000002610. Obstet Gynecol. 2018. PMID: 29688918 No abstract available.
Ulipristal acetate (Esmya): restrictions on use.
[No authors listed] [No authors listed] Drug Ther Bull. 2018 Nov;56(11):127. doi: 10.1136/dtb.2018.11.000033. Epub 2018 Oct 8. Drug Ther Bull. 2018. PMID: 30297449
Safety alert: Esmya (ulipristal acetate) for symptoms of uterine fibroids: restrictions to use and requirement to check liver function before, during and after treatment.1,2....
Safety alert: Esmya (ulipristal acetate) for symptoms of uterine fibroids: restrictions to use and requirement to check liver functio …
Preoperative medical therapy before surgery for uterine fibroids.
Lethaby A, Puscasiu L, Vollenhoven B. Lethaby A, et al. Cochrane Database Syst Rev. 2017 Nov 15;11(11):CD000547. doi: 10.1002/14651858.CD000547.pub2. Cochrane Database Syst Rev. 2017. PMID: 29139105 Free PMC article. Review.
GnRHa versus other medical therapies GnRHa was associated with a greater reduction in uterine volume (-47% with GnRHa compared to -20% and -22% with 5 mg and 10 mg ulipristal acetate) but was more likely to cause hot flushes (OR 12.3, 95% CI 4.04 to 37.48; 5 studies; 183 p …
GnRHa versus other medical therapies GnRHa was associated with a greater reduction in uterine volume (-47% with GnRHa compared to -20% and - …
131 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback